IL321119A - Glycosylated antibodies - Google Patents
Glycosylated antibodiesInfo
- Publication number
- IL321119A IL321119A IL321119A IL32111925A IL321119A IL 321119 A IL321119 A IL 321119A IL 321119 A IL321119 A IL 321119A IL 32111925 A IL32111925 A IL 32111925A IL 321119 A IL321119 A IL 321119A
- Authority
- IL
- Israel
- Prior art keywords
- mannose
- pharmaceutical composition
- composition according
- monoclonal antibody
- sugar chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (7)
1. A pharmaceutical composition comprising a monoclonal antibody comprising a human IgG1 or IgG3 heavy chain constant domain comprising an Asn297 residue, wherein the heavy chain constant domain is glycosylated with a sugar chain at Asn297, the monoclonal antibody characterised in that: (a) the amount of fucose within said sugar chain, related to the sum of G0, G1, Gwithout mannose 4 and mannose 5 as 100% as analyzed by Liquid Chromatography/Mass Spectrometry (LCMS) peptide map analysis is greater than 99%; and (b) the amount of NGNA and N-terminal alpha 1,3 galactose within said sugar chain, related to the sum of G0, G1, G2 without mannose 4 and mannose 5 as 100% as analyzed by Liquid Chromatography/Mass Spectrometry (LCMS) peptide map analysis is 1% or less; wherein the monoclonal antibody is not expressed by CHO cell line DSM ACC2795.
2. The pharmaceutical composition according to claim 1, wherein the amount of NGNA within said sugar chain, related to the sum of G0, G1, G2 without mannose and mannose 5 as 100% is 0.5% or less.
3. The pharmaceutical composition according to any one of the preceding claims wherein the amount of N-terminal alpha 1,3 galactose within said sugar chain related to the sum of G0, G1, G2 without mannose 4 and mannose 5 as 100% is 0.5% or less.
4. The pharmaceutical composition according to any one of the preceding claims wherein the monoclonal antibody is a chimeric, humanised or human antibody.
5. The pharmaceutical composition according to any one of the preceding claims, wherein the monoclonal antibody is of human IgG1 type.
6. A pharmaceutical composition according to any one of the preceding claims, for use in the manufacture of a medicament. - 24 -
7. A pharmaceutical composition according to any one of the preceding claims, for use in the treatment of disease.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007565 | 2006-04-11 | ||
| EP06016203 | 2006-08-03 | ||
| PCT/EP2007/003164 WO2007115813A1 (en) | 2006-04-11 | 2007-04-10 | Glycosylated antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321119A true IL321119A (en) | 2025-07-01 |
Family
ID=38039138
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321119A IL321119A (en) | 2006-04-11 | 2007-04-10 | Glycosylated antibodies |
| IL301499A IL301499B2 (en) | 2006-04-11 | 2007-04-10 | Glycosylated antibodies |
| IL194165A IL194165A0 (en) | 2006-04-11 | 2008-09-17 | Glycosylated antibodies |
| IL233150A IL233150A0 (en) | 2006-04-11 | 2014-06-16 | Glycosylated antibodies |
| IL26920119A IL269201A (en) | 2006-04-11 | 2019-09-09 | Glycosylated antibodies |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301499A IL301499B2 (en) | 2006-04-11 | 2007-04-10 | Glycosylated antibodies |
| IL194165A IL194165A0 (en) | 2006-04-11 | 2008-09-17 | Glycosylated antibodies |
| IL233150A IL233150A0 (en) | 2006-04-11 | 2014-06-16 | Glycosylated antibodies |
| IL26920119A IL269201A (en) | 2006-04-11 | 2019-09-09 | Glycosylated antibodies |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US7846724B2 (en) |
| EP (2) | EP2248831A1 (en) |
| JP (2) | JP5078990B2 (en) |
| KR (2) | KR101275452B1 (en) |
| CN (1) | CN103864923A (en) |
| AR (1) | AR060386A1 (en) |
| AU (1) | AU2007236198B2 (en) |
| BR (1) | BRPI0709960B8 (en) |
| CA (3) | CA2647288C (en) |
| CR (1) | CR10300A (en) |
| EC (1) | ECSP088814A (en) |
| ES (1) | ES2395136T5 (en) |
| IL (5) | IL321119A (en) |
| MA (1) | MA30383B1 (en) |
| MX (1) | MX2008012953A (en) |
| NO (1) | NO20083948L (en) |
| NZ (1) | NZ571277A (en) |
| RU (1) | RU2008144293A (en) |
| WO (1) | WO2007115813A1 (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| EP3199180B1 (en) | 2007-03-08 | 2022-01-05 | Humanigen, Inc. | Epha3 antibodies for the treatment of solid tumors |
| KR101030978B1 (en) * | 2008-07-10 | 2011-04-28 | (주) 에이프로젠 | Recombinant Expression Vector for Animal Cells |
| JP2012515922A (en) | 2009-01-22 | 2012-07-12 | モメンタ ファーマシューティカルズ インコーポレイテッド | Galactose-α-1,3-galactose-containing N-glycans in glycoprotein products derived from CHO cells |
| US8834870B2 (en) | 2009-03-06 | 2014-09-16 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| DK3241435T3 (en) * | 2009-07-08 | 2021-08-23 | Kymab Ltd | ANIMAL MODELS AND THERAPEUTIC MOLECULES |
| AU2010313621C1 (en) | 2009-10-14 | 2015-11-26 | Humanigen, Inc. | Antibodies to EphA3 |
| US20110117087A1 (en) | 2009-10-26 | 2011-05-19 | Reinhard Franze | Method for the production of a glycosylated immunoglobulin |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR101895398B1 (en) | 2011-04-28 | 2018-10-25 | 삼성전자 주식회사 | Method of forming an oxide layer and a method of fabricating a semiconductor device comprising the same |
| EP2741769B1 (en) * | 2011-08-10 | 2019-01-02 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated antibodies |
| UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
| EP2794662A1 (en) * | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| KR20160002713A (en) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| EP2956003A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| JP6480926B2 (en) * | 2013-07-23 | 2019-03-13 | バイオコン・リミテッド | Methods for controlling fucosylation levels in proteins |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| HUE061339T2 (en) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Site-specific glycoengineering of targeting moieties |
| PL3204425T3 (en) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| FR3038517B1 (en) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
| EP3328885A1 (en) * | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| JP6674028B2 (en) | 2016-01-06 | 2020-04-01 | アウトルック セラピューティクス,インコーポレイティド | Regulation of afucosylated species in monoclonal antibody compositions |
| EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| EP3512883A1 (en) | 2016-09-13 | 2019-07-24 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
| CN110300599B (en) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | Antibodies and methods of use thereof |
| CA3064333A1 (en) | 2017-05-29 | 2018-12-06 | Gamamabs Pharma | Cancer-associated immunosuppression inhibitor |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| AU2019226009B2 (en) | 2018-02-21 | 2025-11-20 | Five Prime Therapeutics, Inc. | B7-H4 antibody dosing regimens |
| KR20200144094A (en) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-H4 antibody and methods of use thereof |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| IL307155B2 (en) * | 2018-05-01 | 2025-11-01 | Amgen Inc | Antibodies with a modulated glycan profile |
| AU2019361923B2 (en) | 2018-10-15 | 2026-07-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| JP7575401B2 (en) | 2019-04-03 | 2024-10-29 | ジェンザイム・コーポレーション | Anti-alpha beta TCR binding polypeptides with reduced fragmentation - Patents.com |
| US20220195462A1 (en) | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| WO2021195418A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| CN113512116B (en) | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | anti-IGF-1R antibody and application thereof |
| PH12022553106A1 (en) | 2020-05-17 | 2023-11-20 | Astrazeneca Uk Liimited | Sars-cov-2-antibodies and methods of selecting and using the same |
| IL300257A (en) | 2020-08-10 | 2023-03-01 | Astrazeneca Uk Ltd | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
| EP4214242A1 (en) | 2020-09-15 | 2023-07-26 | RegenxBio Inc. | Vectorized antibodies for anti-viral therapy |
| US20250326861A1 (en) | 2020-09-15 | 2025-10-23 | Regenxbio Inc. | Vectorized lanadelumab and administration thereof |
| WO2022094157A1 (en) | 2020-10-28 | 2022-05-05 | Regenxbio Inc. | Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof |
| AU2021371307A1 (en) | 2020-10-28 | 2023-06-01 | Regenxbio, Inc. | VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS |
| US20230390418A1 (en) | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| KR20230098176A (en) | 2020-10-29 | 2023-07-03 | 리젠엑스바이오 인크. | Vectorized TNF-alpha antagonists for ocular indications |
| US20240309076A1 (en) | 2020-12-29 | 2024-09-19 | Regenxbio Inc. | Tau-specific antibody gene therapy compositions, methods and uses thereof |
| TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
| TW202342510A (en) | 2022-02-18 | 2023-11-01 | 英商Rq生物科技有限公司 | Antibodies |
| CR20240528A (en) | 2022-04-29 | 2025-04-04 | Astrazeneca Uk Ltd | Sars-cov-2 antibodies and methods of using the same |
| TW202400803A (en) | 2022-05-03 | 2024-01-01 | 美商銳進科斯生物股份有限公司 | Vectorized anti-complement antibodies and complement agents and administration thereof |
| TW202417633A (en) | 2022-05-03 | 2024-05-01 | 美商銳進科斯生物股份有限公司 | Vectorized anti-tnf-α inhibitors for ocular indications |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (en) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | How to enhance glycoprotein stability |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5650508A (en) | 1991-12-27 | 1997-07-22 | Georgia Tech Research Corporation | Peptide ketoamides |
| ATE139900T1 (en) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR THE TREATMENT OF B CELL LYMPHOMA |
| JP3442784B2 (en) | 1993-11-23 | 2003-09-02 | ジェネンテク,インコーポレイテッド | Kinase receptor activation assay |
| EP0852951A1 (en) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| JP4334141B2 (en) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| NZ527302A (en) | 2001-01-05 | 2006-10-27 | Abgenix Inc | Antibodies to insulin-like growth factor I receptor |
| US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| ES2283759T3 (en) | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | ANTI-IGF-IR ANTIBODIES AND ITS APPLICATIONS. |
| MXPA04011624A (en) | 2002-05-24 | 2005-03-07 | Schering Corp | Neutralizing human anti-igfr antibody. |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US6819599B2 (en) * | 2002-08-01 | 2004-11-16 | Micron Technology, Inc. | Programmable DQS preamble |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| KR101498588B1 (en) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION |
| KR20050109489A (en) | 2003-02-13 | 2005-11-21 | 화이자 프로덕츠 인크. | Uses of anti-insulin-like growth factor ⅰ receptor antibodies |
| BRPI0408317A (en) | 2003-03-14 | 2006-03-07 | Pharmacia Corp | igf-i receptor antibodies for cancer treatment |
| CA2519113C (en) | 2003-04-02 | 2012-06-05 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| EP2365001A3 (en) | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (en) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME |
| CN1835975B (en) | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | Modified human IGF-1R antibodies |
| AR045614A1 (en) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | ANTIBODIES AGAINST THE RECEIVER OF INTERLEUQUINA- 1 AND USES OF THE SAME |
| FR2861080B1 (en) † | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | ANTIBODIES HAVING AN OPTIMIZED FUCOSE AND GALACTOSE RATE |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| WO2005082415A2 (en) | 2004-02-25 | 2005-09-09 | Dana Farber Cancer Institute, Inc. | Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth |
| BRPI0509412A (en) † | 2004-04-16 | 2007-09-04 | Genentech Inc | polychondritis or multiplex mononeuritis treatment method in mammals and industrialized article |
| CN101014365B (en) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| FR2873699B1 (en) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | NOVEL ANTI-IGF ANTIBODIES IR RT USES THEREOF |
| US7432359B2 (en) * | 2004-09-06 | 2008-10-07 | Kirin Pharma Kabushiki Kaisha | Anti-A33 antibody |
| ES2642787T3 (en) | 2005-10-21 | 2017-11-20 | Lfb Usa, Inc. | Antibodies with enhanced antibody dependent cell cytotoxicity activity, methods for their production and use |
| EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| JP2009532027A (en) * | 2006-03-28 | 2009-09-10 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Anti-IGF-1R antibodies and uses thereof |
| US20080014203A1 (en) * | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US7846724B2 (en) * | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
| MY173295A (en) | 2013-04-16 | 2020-01-14 | Genentech Inc | Pertuzumab variants and evaluation thereof |
-
2007
- 2007-04-05 US US11/732,974 patent/US7846724B2/en active Active
- 2007-04-09 AR ARP070101482A patent/AR060386A1/en not_active Application Discontinuation
- 2007-04-10 IL IL321119A patent/IL321119A/en unknown
- 2007-04-10 EP EP10166861A patent/EP2248831A1/en not_active Withdrawn
- 2007-04-10 BR BRPI0709960A patent/BRPI0709960B8/en active IP Right Grant
- 2007-04-10 JP JP2009504627A patent/JP5078990B2/en active Active
- 2007-04-10 CN CN201410108197.0A patent/CN103864923A/en active Pending
- 2007-04-10 MX MX2008012953A patent/MX2008012953A/en active IP Right Grant
- 2007-04-10 CA CA2647288A patent/CA2647288C/en active Active
- 2007-04-10 AU AU2007236198A patent/AU2007236198B2/en active Active
- 2007-04-10 IL IL301499A patent/IL301499B2/en unknown
- 2007-04-10 NZ NZ571277A patent/NZ571277A/en not_active IP Right Cessation
- 2007-04-10 WO PCT/EP2007/003164 patent/WO2007115813A1/en not_active Ceased
- 2007-04-10 CA CA3128738A patent/CA3128738A1/en active Pending
- 2007-04-10 KR KR1020127002625A patent/KR101275452B1/en active Active
- 2007-04-10 CA CA2849203A patent/CA2849203C/en active Active
- 2007-04-10 ES ES07724105T patent/ES2395136T5/en active Active
- 2007-04-10 RU RU2008144293/13A patent/RU2008144293A/en not_active Application Discontinuation
- 2007-04-10 EP EP07724105.7A patent/EP2007809B2/en active Active
- 2007-04-10 KR KR1020087024721A patent/KR101256257B1/en active Active
-
2008
- 2008-09-16 NO NO20083948A patent/NO20083948L/en not_active Application Discontinuation
- 2008-09-17 IL IL194165A patent/IL194165A0/en unknown
- 2008-09-19 CR CR10300A patent/CR10300A/en not_active Application Discontinuation
- 2008-10-09 EC EC2008008814A patent/ECSP088814A/en unknown
- 2008-10-20 MA MA31310A patent/MA30383B1/en unknown
-
2010
- 2010-09-01 US US12/873,658 patent/US20100322927A1/en not_active Abandoned
-
2011
- 2011-11-17 US US13/298,553 patent/US8703919B2/en active Active
-
2012
- 2012-07-26 JP JP2012165498A patent/JP2012254996A/en active Pending
-
2014
- 2014-03-03 US US14/195,066 patent/US11673958B2/en active Active
- 2014-06-16 IL IL233150A patent/IL233150A0/en unknown
-
2019
- 2019-09-09 IL IL26920119A patent/IL269201A/en unknown
-
2023
- 2023-03-23 US US18/125,691 patent/US12559561B2/en active Active
-
2026
- 2026-01-20 US US19/453,529 patent/US20260146096A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3368572B2 (en) | Anti-pd-1 antibodies and compositions | |
| US11352424B2 (en) | Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies | |
| Radaev et al. | Recognition of IgG by Fcγ receptor: the role of Fc glycosylation and the binding of peptide inhibitors | |
| Liu et al. | Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody | |
| Kobata | The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles | |
| BRPI0614040B8 (en) | isolated antibody that specifically binds to b7rp1, polypeptide, pharmaceutical composition, expression vector, host cell, isolated cell line, and methods for detecting b7rp1 in a biological sample and producing an antibody or polypeptide | |
| WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
| US20210070861A1 (en) | B7-h4 antibody formulations | |
| NO20084082L (en) | Antibodies to insulin-like growth factor 1 receptors and their use | |
| BRPI0709960B8 (en) | monoclonal antibody of the glycosylated human igg1 or igg3 type, its use and method of production and pharmaceutical composition | |
| TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
| FI3569620T3 (en) | Human cgrp receptor binding antibodies | |
| WO2013134743A9 (en) | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof | |
| BRPI0607486B8 (en) | 1243 humanized antibody against hla-dr present in hladr+ cells, pharmaceutical composition, kit and use of said antibodies. | |
| WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
| NZ592087A (en) | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity | |
| WO2006099698A3 (en) | Novel anti-plgf antibody | |
| PL406852A1 (en) | Formulation containing human antibodies for the treatment of disorders associated with TNF-α | |
| SG196688A1 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| WO2004076620A3 (en) | Human antibodies specific for interleukin 15 (il-15) | |
| KR20120075457A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
| US20220288226A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| WO2019184935A1 (en) | Anti-cd27 antibody, antigen-binding fragment thereof and medical use thereof | |
| WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| WO2003073982A3 (en) | Anti-interleukin-1 beta analogs |